However, the efficacy of antiarrhythmic agents has not been rigorously evaluated in patients with ARVC, and limited data are available to support such use of these drugs. The Multidisciplinary ...

This generalization becomes increasingly relevant with age and should inform any approaches to diagnosis, investigation, and management, including the choice of antiarrhythmic drugs. Indeed ...

Antiarrhythmic drugs (AADs) are often used after ablation for atrial fibrillation (AF); the drugs employed vary, but most common are the drugs that were unsuccessful prior to ablation since it ...

Here we review the current experimental basis for several promising antiarrhythmic strategies, with a focus on those targeted against atrial and ventricular fibrillation. Although none of these ...

Elevated baseline resting heart rate (RHR) is associated with an increased risk for incident atrial fibrillation (AF) in ...

With the help of the Valsalva manoeuvre you can help get your heart rhythm back to normal Herersquo;s how it works ...

The pharmacological treatment of VF/pulseless VT is of secondary importance to early defibrillation. Administration of antiarrhythmic drugs is considered in cases of refractory VF/pulseless VT—that is ...

Tissue-engineering techniques are in the works to regrow heart muscle after a heart attack and repair lungs and other organs.

antiarrhythmic agents, or other drugs that prolong QT interval (eg, cisapride, erythromycin, antipsychotics, and TCAs). Monitor ECG in patients with liver cirrhosis. Do not exceed the recommended ...

Monitor and control BP. Avoid in congenital long QT syndrome. CHF, bradyarrhythmias, concomitant antiarrhythmic drugs, or electrolyte disturbances; consider obtaining ECGs and monitor electrolytes ...

Treatment for atrial flutter often begins with antiarrhythmic medications. If these prove ineffective, electrical cardioversion can restore a normal heart rhythm. Because atrial flutter is caused ...

collaboration with Nissan Chemical Industries and Teijin Pharma for the development and commercialisation of an oral atrial-selective antiarrhythmic medication, the acquisition of Medarex ...